- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
home:translations:norwegian [03.13.2019] sallieq [Data] |
home:translations:norwegian [05.10.2019] (current) sallieq [Data] |
||
|---|---|---|---|
| Line 342: | Line 342: | ||
| [[home:food:aim_health:aging|Olmesartan research]] | [[home:food:aim_health:aging|Olmesartan research]] | ||
| + | |||
| + | ==== Response in 5 diagnoses ==== | ||
| + | |||
| + | TOTALS: 864 members;573 report success; 119 report no success; and for 172 results are not clear. | ||
| + | |||
| + | SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91% | ||
| + | |||
| + | Sarcoidosis success 75.8% | ||
| + | |||
| + | Chronic Fatigue Syndrome success 60.1% | ||
| + | |||
| + | Lyme disease success 66.9% | ||
| + | |||
| + | Rheumatoid arthritis success 69.2% | ||
| + | |||
| + | Fibromyalgia success 64.2% | ||
| + | |||
| + | All Other Th1 disease success 59.8% | ||
| ==== Diverse av interesse for skandinaviske lesere ==== | ==== Diverse av interesse for skandinaviske lesere ==== | ||
home/translations/norwegian.txt · Last modified: 05.10.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.